Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.
about
Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1Active immunization in the United States: developments over the past decade.Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in miceParameters underlying successful protection with live attenuated mutants in experimental shigellosisSafety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.Prevention and self-treatment of traveler's diarrhea.Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.Broadly protective Shigella vaccine based on type III secretion apparatus proteins.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Expression of Shigella flexneri ipaB Gene in Tobacco.Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.Progress and pitfalls in Shigella vaccine research.Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.Shigella Vaccine Development: Finding the Path of Least Resistance.Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.
P2860
Q28343287-095455ED-7945-4E33-B8DD-E703E549F96EQ33975799-BCA36C6F-C18C-45DF-A533-9B05D4BDA396Q34002272-D25631F0-3BEF-4100-B1E4-047A3FFCAAE4Q34006071-BD1DF3CA-326D-4E8F-B1EB-00B0ECA4FAC9Q34006223-7E334808-6923-4780-B080-061E0A285373Q34974972-AB3EBB63-86F7-41AF-956C-2BB938325984Q35598035-7CC3C7CA-18F2-4773-8AF6-0221272DA0F6Q35805439-1F58C140-43AE-43A8-8CA9-5B820745D747Q36844719-EE23FD9F-7656-4020-9462-F914426563A7Q36946812-8CB0EB7B-09A3-432A-9C70-0117C4FD493EQ37032264-EFB92821-07A1-4C52-BCEA-C7FE54B48A3BQ37105553-A470040F-F5EB-4AB2-A200-43C5CB3433EEQ37163698-948D90B1-30A1-4582-B99D-09784710E90EQ37477191-824E3496-1988-4954-8F2B-84C5D97F59FBQ39519924-21705725-DAC4-4BF5-8D49-85E651F0F365Q42120657-A642BCA3-2335-4569-8A09-DBB890BDA0B2Q55310096-6DE82E02-F3CF-48D7-9692-4E5F6735D477
P2860
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.
description
1996 nî lūn-bûn
@nan
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Safety and immunogenicity of i ...... accines in Israeli volunteers.
@ast
Safety and immunogenicity of i ...... accines in Israeli volunteers.
@en
type
label
Safety and immunogenicity of i ...... accines in Israeli volunteers.
@ast
Safety and immunogenicity of i ...... accines in Israeli volunteers.
@en
prefLabel
Safety and immunogenicity of i ...... accines in Israeli volunteers.
@ast
Safety and immunogenicity of i ...... accines in Israeli volunteers.
@en
P2093
P2860
P1476
Safety and immunogenicity of i ...... accines in Israeli volunteers.
@en
P2093
Ashkenazi S
Robbins JB
Schneerson R
P2860
P304
P407
P577
1996-10-01T00:00:00Z